Paper Details

  1. Home
  2. Paper Details

Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants.

Author: , AnugulruengkittSuvaporn, ChokephaibulkitKulkanya, CresseyTim R, JantarabenjakulWatsamon, OunchanumPradthana, PancharoenChitsanu, PunnahitanonSunti, PuthanakitThanyawee, SophonphanJiratchaya, SrirompotongUssanee, SuntarattiwongPiyarat

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Zidovudine/lamivudine/nevirapine is safe for neonatal postexposure prophylaxis (PEP) for HIV-exposed infants.
Paper Details　
Original Abstract of the Article :
Combination antiretroviral drug regimens are increasingly preferred for neonatal postexposure prophylaxis (PEP) among HIV-exposed infants with high-risk of transmission. We evaluated the adverse events associated with the use of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP) for neonatal PEP dur...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/INF.0000000000002426

データ提供：米国国立医学図書館（NLM）

Protecting Infants from HIV

Combating HIV transmission in infants is a vital research area. This study delves into the safety of a specific antiretroviral drug regimen used for neonatal postexposure prophylaxis (PEP) in infants at high risk of HIV transmission. The researchers looked at the safety profile of a combination therapy involving zidovudine (ZDV), lamivudine (3TC), and nevirapine (NVP) during the first 6 weeks of life.

This study is like a guidebook for navigating the delicate balance of protecting infants from HIV without causing unwanted side effects. The researchers analyzed the adverse events associated with this drug regimen to ensure it provides effective protection without jeopardizing the infant's health.

Safeguarding the Vulnerable

The study provides critical information on the safety and effectiveness of a specific drug regimen for PEP in high-risk infants. These findings are crucial for developing evidence-based treatment strategies and optimizing the care of vulnerable infants.

A Beacon of Hope in the Desert of HIV

This research is like a well in the desert for infants vulnerable to HIV. It offers a safe and effective approach to protect infants, providing a vital lifeline and hope for a healthy future.

Dr. Camel's Conclusion

The researchers have provided a valuable roadmap for protecting infants from the dangers of HIV transmission. This research is a beacon of hope, illuminating the path toward safer and more effective treatments.

Date :
  1. Date Completed 2020-04-29
  2. Date Revised 2020-04-29
Further Info :

Pubmed ID

31365477

DOI: Digital Object Identifier

10.1097/INF.0000000000002426

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.